Home›Search›Expert Opinion on Emerging Drugs

Expert Opinion on Emerging Drugs

Taylor and Francis Ltd. · United Kingdom · Est. 1997

ISSN1472-8214eISSN1744-7623

SJR Q1✓ WOS SCIE✓ Scopus / SJR

/ 100

Medium Risk

Score Breakdown

✓ WoS SCIE/SSCI+25

✓ Scopus Q1+25

Total60

Journal Impact Factor

This journal is indexed in Web of Science (JCR) and has an official Journal Impact Factor. View the current value on the journal’s page ↗

SJR Score

1.034

H-Index

CiteScore

View ↗

Scopus metric · on the journal’s page

SNIP

0.538

Total Works

1,014

Total Citations

21,385

2yr Mean Citedness

4.84

Free JIF alternative

Retractions

Source: Retraction Watch

Aims & Scope✦ Inferred from recent articles

This journal focuses on the evaluation of emerging drugs and therapeutic strategies for a range of diseases. It covers novel treatments for solid tumors, epilepsy, rosacea, atopic dermatitis, age-related macular degeneration, immune thrombocytopenia, sickle cell disease, obesity, cancer cachexia, myelin oligodendrocyte glycoprotein antibody-associated disease, glaucoma, and bullous pemphigoid. The journal highlights advancements in drug development, including antibody-based approaches, targeted therapies, gene therapies, and microbiome-based interventions, as well as discusses clinical trial data, efficacy, safety profiles, and future positioning of these agents.

AI-summarised from recent articles · verify on publisher page →

⚡ Speed vs Prestige

How does this journal balance review speed with impact level?

SJR Rank

Top 25% in field

General Information

Country / RegionUnited Kingdom

Primary LanguageEnglish

1st Year Published1997

FrequencyBiannual

StatusActive (last: 2025)

Total Publications1,014

Publisher OrgTaylor & Francis

Visit Journal Website

Submission Info

Peer Review—

Review Time—

Acceptance Rate—

OA License—

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Think.Check.Submit Compliance

thinkchecksubmit.org

6/12 · 50%

✅

Do you know the journal / publisher?

Taylor and Francis Ltd.

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

1472-8214 / 1744-7623

✅

Indexed in a trusted database?

WoS, Scopus

❌

Peer review process documented?

N/A

❌

Follows ethical publishing standards (COPE)?

N/A

❌

APC fees clearly disclosed?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

❌

Plagiarism detection in place?

N/A

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Times cited

2019

2020

2021

2022

2023

2024

2025

2026

Source: OpenAlex · Note: citations accumulate over time so older years appear higher

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

PharmacologyQ1

Pharmacology (medical)Q1

Subject Classification

Web of Science Categories

Pharmacology & Pharmacy

Scopus Categories

PharmacologyPharmacology (medical)

Research Topics (OpenAlex)

Asthma and respiratory diseasesRetinal Diseases and TreatmentsCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCAR-T cell therapy researchRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and PathogenesisHER2/EGFR in Cancer ResearchChronic Lymphocytic Leukemia ResearchPhosphodiesterase function and regulation